Venture capital-backed pharmaceutical company Flexion Therapeutics could raise up to $86m for its IPO on the Nasdaq.
BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers.
Flexion is company developing innovative therapeutics for musculoskeletal disorders. The company is currently advancing a portfolio of drug candidates that together have the potential to treat pain from mild, moderate and severe forms of osteoarthritis.
In 2009 the company completed a $33m Series A financing round led by Versant Ventures and included founding investors 5AM Ventures and Sofinnova Partners.
Copyright © 2014 AltAssets